» Articles » PMID: 1693497

Persistent and Recurrent Neovascularization After Krypton Laser Photocoagulation for Neovascular Lesions of Age-related Macular Degeneration. Macular Photocoagulation Study Group

Overview
Journal Arch Ophthalmol
Specialty Ophthalmology
Date 1990 Jun 1
PMID 1693497
Citations 15
Affiliations
Soon will be listed here.
Abstract

The persistence and recurrence of choroidal neovascularization after initial treatment with laser photocoagulation have been shown to be major contributors to loss of visual acuity. The 247 eyes assigned to krypton red laser photocoagulation in the Age-Related Macular Degeneration Study-Krypton Laser were examined to describe the incidence, timing, visual impact, and potential risk factors for persistence and recurrence. Persistent neovascularization detected within 6 weeks of initial treatment was observed in 32% of treated eyes, and recurrent neovascularization was estimated by life-table methods to develop in an additional 47% over a 5-year period. Both persistence and recurrence were accompanied by an increased frequency of severe visual loss. The persistence rate among eyes having 10% or more of the foveal side of the neovascular membrane not covered by treatment was twice as high as in eyes having more extensive coverage. Patients having a fellow eye with a neovascular membrane or scar, a fellow eye with 20 or more drusen in the central macula, or a fellow eye with nongeographic atrophy at initial visit had more recurrences than patients without these characteristics. Ophthalmologists treating similar lesions may be able to reduce persistent neovascularization and the associated visual loss by covering the entire lesion with treatment.

Citing Articles

Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Chan C, Jain A, Sadda S, Varshney N Trans Am Ophthalmol Soc. 2015; 112:160-98.

PMID: 25646034 PMC: 4307397.


Management of significant reactivation of old disciform scars in wet age-related macular degeneration.

Coco R, Sala-Puigdollers A BMC Ophthalmol. 2014; 14:82.

PMID: 24965122 PMC: 4077557. DOI: 10.1186/1471-2415-14-82.


Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration.

Riazi-Esfahani M, Ahmadieh H, Faghihi H, Piri N, Taei R, Karkhaneh R J Ophthalmic Vis Res. 2013; 3(2):95-101.

PMID: 23479530 PMC: 3589227.


Laser treatment in 341 patients with exudative age-related macular degeneration.

Atmaca L, Idil A, Atmaca-Sonmez P Int J Ophthalmol. 2012; 4(1):73-7.

PMID: 22553614 PMC: 3340680. DOI: 10.3980/j.issn.2222-3959.2011.01.17.


Complement, age-related macular degeneration and a vision of the future.

Gehrs K, Jackson J, Brown E, Allikmets R, Hageman G Arch Ophthalmol. 2010; 128(3):349-58.

PMID: 20212207 PMC: 4405117. DOI: 10.1001/archophthalmol.2010.18.